ANGLE: Parsortix commercial traction would be transformational
ANGLE is progressing its proprietary Parsortix cancer diagnostic platform through several key inflection points over the next 24 months, most notably FDA approval. In parallel, it has initiated commercialisation through the creation of two clinical laboratories (in the UK and US), which can offer services to the pharma industry and LDTs (Laboratory Developed Tests) for the clinical market. Parsortix is an elegant microfluidic device that captures circulating tumour cells (CTCs) for analysis. Such liquid biopsies will be employed increasingly not only in initial diagnosis, but to monitor and guide treatment. Our DCF-based valuation is £549m, or 255p per share.ANGLE is a holding company. Through its subsidiares, Co. operates as a medical diagnostic company focusing on the development of products in the fields of cancer diagnostics and foetal health. Co. develops products for use in rare cell diagnostics that enable early identification of an individual's condition for the prevention, treatment, and monitoring of disease. Co.'s principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy (non-invasive cancer diagnostics).
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.